217 related articles for article (PubMed ID: 32282418)
1. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
3. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
[TBL] [Abstract][Full Text] [Related]
4. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Rutrick D; Learned SM; Boyett B; Hassman D; Shinde S; Zhao Y
J Subst Use Addict Treat; 2023 Nov; 154():209155. PubMed ID: 37657559
[TBL] [Abstract][Full Text] [Related]
5. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
[TBL] [Abstract][Full Text] [Related]
6. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
[TBL] [Abstract][Full Text] [Related]
7. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
[No Abstract] [Full Text] [Related]
8. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
[TBL] [Abstract][Full Text] [Related]
9. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
[TBL] [Abstract][Full Text] [Related]
11. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
12. Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
Boyett B; Nadipelli VR; Solem CT; Chilcoat H; Bickel WK; Ling W
J Addict Med; 2023 Mar-Apr 01; 17(2):182-189. PubMed ID: 36111991
[TBL] [Abstract][Full Text] [Related]
13. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G
Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443
[TBL] [Abstract][Full Text] [Related]
14. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
Jones AK; Ngaimisi E; Gopalakrishnan M; Young MA; Laffont CM
Clin Pharmacokinet; 2021 Apr; 60(4):527-540. PubMed ID: 33135125
[TBL] [Abstract][Full Text] [Related]
16. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
Kranzler HR; Lynch KG; Crist RC; Hartwell E; Le Moigne A; Laffont CM; Andorn AC
Int J Neuropsychopharmacol; 2021 Feb; 24(2):89-96. PubMed ID: 32920647
[TBL] [Abstract][Full Text] [Related]
17. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
18. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment.
Gray JR; Kehoe LG; Peckham AM; Wakeman SE
J Addict Med; 2023 Mar-Apr 01; 17(2):227-229. PubMed ID: 36074787
[TBL] [Abstract][Full Text] [Related]
20. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
